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  Genome-wide association studies in bipolar disorder (BD)1 have implicated a single-
nucleotide polymorphism (rs1006737, G-A) in the CACNA1C gene, which encodes for the alpha 1c 
(CAV1.2) subunit of the voltage-gated, L-type calcium channel. Neuroimaging studies of healthy 
individuals report that this risk allele modulates brain function within limbic (amygdala, anterior 
cingulate gyrus) and hippocampal regions during tasks of reward processing2,3 and episodic 
memory.4 Moreover, animal studies suggest that the CaV1.2 L-type calcium channels influence 
emotional behaviour through enhanced neurotransmission via the lateral amygdala pathway.5 On 
the basis of this evidence, we tested the hypotheses that the CACNA1C rs1006737 risk allele will 
modulate neural responses within predefined prefrontal and subcortical regions of interest during 
emotional face processing and that this effect would be amplified in BD patients.  
 A total of 116 individuals of white British descent comprising 41 euthymic patients with BD, 
25 of their first-degree relatives without any Axis I disorder and 50 healthy controls, were genotyped 
for the CACNA1C rs1006737 polymorphism (Table 1, Supplementary Material). These comprised 54 
G homozygotes (BD patients: N=17; relatives: N=9; controls: N=28), 47 AG heterozygotes (BD 
patients: N=19; relatives: N=10; controls: N=18) and 15 A homozygotes (BD patients: N=5; relatives: 
N=6; controls: N=4), in Hardy-Weinberg equilibrium (P = 0.92). Because of their small number AA 
individuals were considered together with AG heterozygotes within each diagnostic group (BD 
patients: N=24; relatives: N=16;  controls: N=22) in further analyses. There was no effect of genotype 
or genotype by diagnosis interaction on demographic variables (P > 0.15). Carriers of the CACNA1C 
rs1006737 risk allele had higher depressive and manic symptom scores (P = 0.01) with this effect 
being more pronounced in patients (P < 0.02) (Table 1, Supplementary Material). 
 All participants completed a functional magnetic resonance imaging facial affect recognition 
task comparing fearful with neutral faces (Supplementary material), which had previously been used 
in imaging genetics.6 Anatomical and gradient-echo echoplanar imaging data were acquired during 
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the same session using a 1.5 T GE Neuro-optimized Signa Magnetic Resonance system (General 
Electric, Milwaukee, WI, USA). We examined the effect of genotype, group and their interaction on 
predefined prefrontal (lateral and medial prefrontal cortex and anterior cingulate cortex) and 
subcortical (amygdala, hippocampus) regions of interest known to be associated with fear facial 
affect processing6,7 or to be modulated by CACNA1C rs1006737.2,3,4 Full factorial analysis of 
variance with response time, age and symptom scores as covariates was implemented in SPM5 
(http:/www.fil.ion.ucl.ac.uk/spm/software/spm5) (Supplementary material); statistical inferences 
were based on a threshold of P < 0.05 with family-wise error correction. 
 Independent of diagnostic group, the right amygdala ? ?(x=26 y = 2 z = 26 z-score = 4.60) 
showed greater activation during fear-face recognition relative to neutral faces in AA/AG compared 
with GG individuals (Figure 1). A significant effect of group was noted in the right ventrolateral 
prefrontal cortex ?(vlPFC; x=52 y=38 z = 10 z-score = 3.71). A significant ?genotype diagnosis 
interaction was also observed in th ?e right vlPFC (x=54 y=36 z = 12 z-score = 3.64). The right vlPFC 
expressed reduced activation in individuals with the high-risk allele compared with those with the 
low-risk variant in BD patients, but not in their relatives or controls (Figure 1). 
 This report confirms previous findings that genetic variation in the CACNA1C gene 
modulates amygdala function during emotional processing.2 This effect is, however, diagnosis 
independent. Moreover, we provide the first formal evidence of a disease-specific influence of the 
CACNA1C genotype on brain function The present findings suggest that the CACNA1Crs1006737 
polymorphism impacts on vlPFC activation during fear processing in BD carriers of the risk allele but 
not their unaffected relatives. The ventral PFC is thought to contribute to emotional regulation by 
modulating amygdala activation particularly in response to environmental threats.7 
 It is still unclear whether rs1006737 or another variant in linkage disequilibrium is causally 
linked to the risk of BD and to our findings. However, our results implicate CACNA1C in functional 
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changes within emotional systems that are consistent with increased amygdala reactivity and 
reduced prefrontal control. 
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Figure 1 Statistical parametric map (SPM) showing the effect of CACNA1C rs1006737 polymorphism 
on amygdala function during fear-face processing in bipolar disorder (BD) patients, their unaffected 
?relaOves and controls (top), and genotype diagnosis interacOon in the ventrolateral prefrontal 
cortex (vlPFC) (bottom); SPM thresholded at P < 0.05, family-wise error corrected. 
